Timothy Cleland, MD
Retina Specialist · San Antonio, TXNPI 1578676037
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,342 of the $6,172 with a category attached, or 70.3%. 17 manufacturers reported payments, led by Novo Nordisk AS at 37.6% of the total. Reporting peaked in 2019 at $2,644 and has fallen 57.4% since, to $1,127 in 2025.
Across 102 payments — averaging $60.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2K
- AbbVie$757
- Genentech USA, Inc.$572
- Regeneron Healthcare Solutions, Inc.$459
- Apellis Pharmaceuticals, Inc.$405
- Alcon$301
- plus $1K from 11 others
Across 111 payments — averaging $4797.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$470K
- Apellis Pharmaceuticals, Inc.$61K
- AbbVie$900
What the payments were for
- Travel & lodging$1,79829%
- Food & beverage$4,34270%
- Entertainment$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $2,323 |
| AbbVie(2 entities) | 35 | $757 |
| Genentech USA, Inc. | 11 | $572 |
| Regeneron Healthcare Solutions, Inc. | 15 | $459 |
| Apellis Pharmaceuticals, Inc. | 4 | $405 |
| Alcon | 4 | $301 |
| Biotissue Holdings Inc. | 2 | $293 |
| Novartis | 6 | $202 |
| Sight Sciences, Inc. | 1 | $137 |
| Aerie Pharmaceuticals, Inc. | 3 | $133 |
| Alimera Sciences, Inc. | 6 | $122 |
| Amgen | 1 | $122 |
| Optovue, Inc. | 1 | $120 |
| ANI Pharmaceuticals, Inc. | 3 | $94 |
| Astellas Pharma US Inc | 4 | $73 |
| Optos, Inc. | 1 | $32 |
| Ocular Therapeutix, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,172 in reported general payments places this provider in the 70th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 38 | $1,230 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 68 | $658 |
| Brimonidine Tartrate | 23 | $496 |
| Dorzolamide Hcl | 13 | $280 |
| Atropine Sulfate | 12 | $267 |
| Latanoprost | 19 | $201 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in San Antonio
- Moises ChicaSan Antonio$43K
- Sarah HolySan Antonio$18K
- Richard LaneSan Antonio$17K
- Duncan FriedmanSan Antonio$9K
- Thomas OeiSan Antonio$9K
- Lina MaroufSan Antonio$4K
- Dianne BarrettSan Antonio$4K
- Abumere AkinwaleSan Antonio$3K
- Rushil RaoSan Antonio$3K
- Enchun LiuSan Antonio$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.